Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation : the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT / L. Garderet, S. Iacobelli, P. Moreau, F. Onida, C. Koenecke, T. Pabst, C. Doyen, C. Crawley, R. Hajek, W. Linkesch, J.L. Harousseau, M. Michallet, Z. Doran, T. De Witte, D. Niederwieser, G. Gahrton, C. Morris on behalf of the Chronic Leukemia Working Party of the EBMT. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 43:Supplement 1(2009 Apr), pp. S30-S30. ((Intervento presentato al 35. convegno Annual Meeting of the European Group for Blood and Marrow Transplantation tenutosi a Göteborg, Sweden nel 2009.
Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation : the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT
F. Onida;
2009
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.